3 Changes We Should Make to Address the Gender Pay Gap in Medicine

Women in medicine earn about 20 percent less than men. That is a problem for multiple reasons. It is, of course, not fair to the women who go through the same training and have the same skills as their male counterparts. Worse still, if well-qualified women are discouraged from entering the profession because of this … Continue reading “3 Changes We Should Make to Address the Gender Pay Gap in Medicine”

Dear Tom Price: Bundled Payments Help Patients and Reduce Costs

With all the talk of repealing Barack Obama’s Affordable Care Act (ACA), people have been taking a closer look at what the law has done for our healthcare system. It turns out the ACA is about a lot more than the problematic healthcare marketplaces. There’s the extension of parental insurance coverage to age 26 and … Continue reading “Dear Tom Price: Bundled Payments Help Patients and Reduce Costs”

Wake Up, Pharma—Trump Is Not Your Savior

Since the election, leaders in biotechnology and pharmaceuticals are acting like they got away with robbery. The Nasdaq Biotechnology Index went up 9 percent overnight on November 8th. With Donald Trump coming into office, the whole industry seems to have breathed a sigh of relief that the status quo—a continuous race toward higher prices—will last … Continue reading “Wake Up, Pharma—Trump Is Not Your Savior”

Should We Rewrite the Human Genome?

Scientists are engineering a new living thing: a radically modified version of the lowly bacterium E. coli. In an article in Science from August, researchers at Harvard University described an ongoing project to build the genetic code of E. coli from scratch, but with major revisions to create a new strain unlike any in existence. The modified E. coli is … Continue reading “Should We Rewrite the Human Genome?”

Sanofi’s Experience With Dengvaxia May Speed Development of Zika Vaccine

Dengvaxia, the first licensed vaccine for dengue virus, has now been approved in 11 countries where dengue is endemic. But sales of the vaccine, which were initially projected to reach €200 million this year, barely reached €20 million in the first half of the year, with little sign of picking up. Sanofi Pasteur, the group … Continue reading “Sanofi’s Experience With Dengvaxia May Speed Development of Zika Vaccine”

How Doctors Think About Drug Prices

There are a lot of factors involved in drug pricing that don’t enter my head when I’m seeing a patient. The three letters “PBM,” for example (pharmacy benefit manager), have never crossed my mind when I’m writing a prescription. Nor has the word “rebate.” Or the phrase “pay for delay.” Or “marketing exclusivity.” Basically, I … Continue reading “How Doctors Think About Drug Prices”

MGH Goes Epic: What I Learned in the Trenches

On April 2 at Massachusetts General Hospital (MGH), the green charts went away. Every morning around 6:30 am since starting residency, my co-interns and I had frantically scrambled around the halls searching for these plastic binders, which contained the sole record of our patients’ vital signs. It was a ritual that blended equal parts anxiety, … Continue reading “MGH Goes Epic: What I Learned in the Trenches”

Dear Biopharma: Give Us Better Therapies for Pain

The CDC released on March 15th new guidelines that advise strict limits on the prescription of opioids for pain. These guidelines respond to a stunning increase in deaths and addiction related to the prescription of opioids like OxyContin and Percocet. The CDC recommended against providing patients more than a seven-day supply of opioids for acute … Continue reading “Dear Biopharma: Give Us Better Therapies for Pain”

CRISPR: The Path to Clinical Trials

If you have read a newspaper lately, there is a good chance you have heard about CRISPR-Cas9, the versatile gene editing technology. Over the past several months, legal battles over intellectual property, ethical concerns over editing of the human germline, jaw-dropping partnerships with pharma, and talk of IPOs have crescendoed to a steady roar, reaching … Continue reading “CRISPR: The Path to Clinical Trials”